Biomarker foxf2 for gastric cancer
AssigneeThe Chinese University of Hong Kong
InventorsJun Yu, Joseph Jao Yiu Sung
Life of this patent
Estimating the term…
Abstract
The present invention provides a method for diagnosing and determining prognosis of gastric cancer in a subject by detecting suppressed expression of the FOXF2 gene, which in some cases is due to elevated methylation level in the genomic sequence of this gene. A kit and device useful for such a method are also provided. In addition, the present invention provides a method for treating gastric cancer by increasing FOXF2 gene expression or activity.
Claims23
A method for assessing risk for gastric cancer in a subject, comprising the steps of:
- (a) measuring expression level of FOXF2 in a sample taken from the subject,
- (b) comparing the expression level obtained in step (a) with a standard control, and
- (c) determining the subject, who has a reduced FOXF2 expression level compared with the standard control, as having an increased risk for gastric cancer.
A method for assessing risk for gastric cancer in a subject, comprising the steps of:
- (a) treating DNA from a gastric sample taken from the subject with an agent that differentially modifies methylated and unmethylated DNA;
- (b) determining number of methylated CpGs in a genomic sequence, which is SEQ ID NO:9 or a fragment thereof comprising at least 5 CpGs, and
- (c) comparing the number of methylated CpGs from step (b) with the number of methylated CpGs in the genomic sequence from a non-cancer gastric sample and processed through steps (a) and (b);
- and
- (d) determining the subject, whose gastric sample contains more methylated CpGs in the genomic sequence determined in step (b) compared to the number of methylated CpGs with the number of methylated CpGs in the genomic sequence from a non-cancer gastric sample and processed through steps (1) to (3), as having an increased risk for gastric cancer compared with a healthy subject not diagnosed with gastric cancer.
A method for assessing likelihood of mortality from gastric cancer in a gastric cancer patient, comprising the steps of:
- (a) treating DNA from a gastric cancer sample taken from a first gastric cancer patient with an agent that differentially modifies methylated and unmethylated DNA;
- (b) determining number of methylated CpGs in a genomic sequence, which is SEQ ID NO:9 or a fragment thereof comprising at least 5 CpGs, and
- (c) comparing the number of methylated CpGs from step (b) with the number of methylated CpGs in the genomic sequence from another gastric cancer sample of the same type obtained from a second gastric cancer patient and processed through steps (a) and (b);
- and
- (d) determining the first patient, whose gastric cancer sample contains more methylated CpGs in the genomic sequence determined in step (b) compared to the number of methylated CpGs with the number of methylated CpGs in the genomic sequence from the gastric cancer sample obtained from the second patient and processed through steps (1) to (3), as having an increased likelihood from gastric cancer compared with the second gastric cancer patient.
-21. (canceled)
A kit for detecting gastric cancer in a subject, comprising (1) a standard control that provides an average amount of FOXF2 protein or FOXF2 mRNA;
- and (2) an agent that specifically and quantitatively identifies FOXF2 protein or FOXF2 mRNA.
-27. (canceled)
A method for inhibiting growth of a gastric cancer cell, comprising contacting the gastric cancer cell with an effective amount of a polypeptide comprising the amino acid sequence set forth in SEQ ID NO:14 or a nucleic acid comprising a polynucleotide sequence encoding SEQ ID NO:14.
-32. (canceled)
Dependencies are inferred from the claim text.